657 related articles for article (PubMed ID: 10456462)
1. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
[TBL] [Abstract][Full Text] [Related]
2. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
[TBL] [Abstract][Full Text] [Related]
3. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
[TBL] [Abstract][Full Text] [Related]
4. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR
Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203
[TBL] [Abstract][Full Text] [Related]
5. [Endovenous thrombolysis in acute myocardial infarct. The experience in a community hospital. An analysis of 120 patients].
Jorge Sdo C
Arq Bras Cardiol; 1992 Jul; 59(1):23-30. PubMed ID: 1341143
[TBL] [Abstract][Full Text] [Related]
6. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
[TBL] [Abstract][Full Text] [Related]
7. New developments in thrombolytic therapy.
Collen D; Gold HK
Verh K Acad Geneeskd Belg; 1989; 51(3):191-228; discussion 229. PubMed ID: 2686261
[TBL] [Abstract][Full Text] [Related]
8. [New substances and dosages for thrombolysis in acute myocardial infarct].
Zeymer U; Neuhaus KL
Z Kardiol; 1993; 82 Suppl 2():137-41. PubMed ID: 8328192
[TBL] [Abstract][Full Text] [Related]
9. [Platelet activation in the early phases of acute myocardial infarction].
Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
[TBL] [Abstract][Full Text] [Related]
10. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
11. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
[TBL] [Abstract][Full Text] [Related]
12. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
Okada K; Lijnen HR; Moreau H; Vanderschueren S; Collen D
Thromb Haemost; 1996 Dec; 76(6):857-9. PubMed ID: 8972000
[TBL] [Abstract][Full Text] [Related]
13. Impact of metabolic syndrome on coronary patency after thrombolytic therapy for acute myocardial infarction.
Yasar AS; Bilen E; Bilge M; Arslantas U; Karakas F
Coron Artery Dis; 2009 Sep; 20(6):387-91. PubMed ID: 19696662
[TBL] [Abstract][Full Text] [Related]
14. Association between admission mean platelet volume and coronary patency after thrombolytic therapy for acute myocardial infarction.
Yaşar AS; Bilen E; Yüksel IO; Arslantaş U; Karakaş F; Kirbaş O; Bilge M
Turk Kardiyol Dern Ars; 2010 Mar; 38(2):85-9. PubMed ID: 20473008
[TBL] [Abstract][Full Text] [Related]
15. [Development of new thrombolytic substances].
Zeymer U; Neuhaus KL
Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
[TBL] [Abstract][Full Text] [Related]
16. Alterations in the fibrinolytic system components during acute myocardial infarction.
Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
[TBL] [Abstract][Full Text] [Related]
17. Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction.
Wagner A; Herkner H; Schreiber W; Bur A; Woisetschläger C; Stix G; Laggner AN; Hirschl MM
Thromb Haemost; 2002 Aug; 88(2):180-5. PubMed ID: 12195686
[TBL] [Abstract][Full Text] [Related]
18. [The safety and efficacy of systemic salvage thrombolysis in acute myocardial infarct].
Sarullo FM; Schicchi R; Schirò M; Americo L; Bonnì G; Faraone N; Di Pasquale P; Castello A; Mauri F
Ital Heart J Suppl; 2000 Jan; 1(1):81-7. PubMed ID: 10832123
[TBL] [Abstract][Full Text] [Related]
19. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction.
Sane DC; Stump DC; Topol EJ; Sigmon KN; Kereiakes DJ; George BS; Mantell SJ; Macy E; Collen D; Califf RM
Thromb Haemost; 1991 Mar; 65(3):275-9. PubMed ID: 1904653
[TBL] [Abstract][Full Text] [Related]
20. [t-PA in thrombolytic therapy of acute myocardial infarct].
Rutsch W; Schmutzler H
Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
